AOC3 and Hepatic fibrosis: As liver inflammation is a key factor in the progression of NASH and related liver fibrosis (Xu et al., 2022), VAP-1 inhibitors can be used as promising anti-inflammatory agents (Lalor et al., 2007) that could be targeted in combination with other synergistic mechanisms, such as anti-fibrosis and lipid metabolism modulators.